Biohaven Ltd.

NYSE:BHVN

Biotechnology

Healthcare
$12.90 -1.62%

-$0.22 today

Market cap
$1.95B
Beta
3.31
P/E (TTM)
-3.1
EPS (TTM)
-$4.39
52W Low $7.48High $18.57

Volume 2.32M

Average 2.47M

BHVN Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Biohaven Ltd.NYSE: BHVN

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit remains negative

Q2 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$2.07M.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$516.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
-$4.14M— YoY
LTMJun 2026
-$2.07M— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(4.14M) USD
Year-over-year change
—

Gross Profit vs competitors

How BHVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
BHVN Competitors
Gross Profit for BHVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMCRImmunocore Holdings plcLTM Mar 2026$381.15M USD+15.4%+28.0%98.8%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$256.89M USD+42.5%+39.6%81.6%
VERAVera Therapeutics, Inc.LTM Jun 2026$0 USD———
PHVSPharvaris N.V.LTM Sep 2026-€106.45K EUR-9.7%——
SIONSionna Therapeutics, Inc.LTM Mar 2026-$453K USD-172.9%——
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$742K USD+99.6%—662.5%
IMNMImmunome, Inc.LTM Sep 2026-$753K USD+98.1%——
BHVNBiohaven Ltd.LTM Jun 2026-$2.07M USD———
ABCLAbCellera Biologics Inc.LTM Sep 2026-$12.67M USD-135.9%-52.0%18.7%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-$101.61M USD+44.5%+5.1%153.7%
ZBIOZenas BioPharma, Inc.LTM Mar 2026-$103.75M USD-98.2%——
Peer median (excluding BHVN) —+15.4%+16.6%98.8%

Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00004.14M
Gross Profit0000(4.14M)
Gross Margin—————
Research & Development181.49M437.07M373.28M795.87M635.07M
Selling, General & Admin37.41M130.86M62.77M89.24M106.17M
Operating Expenses218.9M567.93M436.05M885.11M741.24M
Depreciation & Amortization1.39M1.39M6.91M7.86M9.92M
EBITDA(211.04M)(568.46M)(402.64M)(837.83M)(727.46M)
EBITDA Margin—————
Operating Income(218.9M)(567.93M)(436.05M)(885.11M)(745.38M)
Operating Margin—————
Interest Income0017.73M21.33M14.59M
Interest Expense00000
Other Income / Expenses6.47M(1.91M)26.5M39.42M8M
Income Before Tax(212.43M)(569.84M)(409.55M)(845.69M)(737.38M)
Pre-Tax Margin—————
Income Tax Expense1.37M438K(1.38M)735K1.44M
Net Income(213.8M)(570.28M)(408.17M)(846.42M)(738.82M)
Net Margin—————
EPS (Basic)(5.97)(12.75)(5.73)(9.28)(6.86)
EPS (Diluted)(5.97)(12.75)(5.73)(9.28)(6.86)
Weighted Avg Shares35.82M44.74M71.2M91.23M107.62M
Weighted Avg Shares (Diluted)35.82M44.74M71.2M91.23M107.62M

Biohaven Ltd.

NYSE:BHVN

Intrinsic Alpha fair value

Locked

Current Price

$12.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.